Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment

Introduction

Preeclampsia is a special type of hypertensive disorders complicating pregnancy (HDCP) which is characterized by hypertension, proteinuria, hematological complications, and uteroplacental dysfunction (von Dadelszen and Magee, 2014). The fetal development is also significantly influenced by the pathogenesis of PE, such as amniotic fluid reduction, oxygenation defect, and growth restriction (Douglas and Redman, 1994). During the pathogenesis of PE, the dysfunction in maternal vascular system and the abnormal activation of maternal-fetal immune system are proved to be the two main factors (Laresgoiti-Servitje, 2013). The worldwide prevalence of PE in all pregnant women is from 3 to 8% and nearly 18% maternal deaths are caused by PE based on its high maternal morbidity and mortality (Anderson et al., 2012). The primary prevention of PE is mainly performed through the treatment of aspirin, vitamin D, and low-dose calcium (Henderson et al., 2014). The termination of pregnancy or fetus delivery is thought to be the only definitive treatment for PE (World Health Organization [WHO], 2011). Although there has been great progress in the study of PE, the prediction and prevention of PE development is still a big challenge.

PE is proved to be an anti-angiogenic state. Soluble fms-like tyrosine kinase 1 (sFLT-1) is a shorter form of FLT-1 which lacks the intra-cytoplasmic and transmembrane domain and thus can circulates freely in maternal circulation (Salahuddin et al., 2007). The ability of binding with vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) makes sFLT-1 to be the decoy receptor of these two factors in the maternal circulation (Rana et al., 2012). The sFLT1:PlGF ratio is proved to fluctuate during the normal pregnant. sFLT1 stays at a stable level till week 29–30 and then increases to a peak at week 40 (Palm et al., 2011). Meanwhile, The sFLT1:PlGF ratio decreases in week 9–12, stays at a low level from week 19–20 to 37–38, and then increases in week 39–40 (Palm et al., 2011). The tightly regulated sFLT1:PlGF ratio during pregnant is crucial for both placenta and fetal development. The elevated sFLT-1 level is observed in patients with PE (Levine et al., 2004). The pathogenesis of PE triggers the increasing of sFLT1 level in maternal circulation (Herraiz et al., 2018). The up-regulated sFLT-1 level in the maternal circulation decrease the levels of VEGF and PlGF and generates the endothelial dysfunction (Levine et al., 2006). It has been reported that sFLT-1 expression is up-regulated in the placenta and generated by villous and extravillous trophoblasts (Ahmad and Ahmed, 2004). Therefore, the overexpressed sFLT1 in placenta is considered to be a potential therapeutic target for PE. How to achieve efficient intervention of sFLT1 expression in the placenta is an urgent problem to be solved.

In recent, it has been proved that the systemically delivered sFLT1 siRNAs which are cholesterol conjugated and full chemical stabilized can accumulate in placentas, inhibit the expression of sFLT1, and alleviate proteinuria and hypertension (Turanov et al., 2018). Chondroitin sulfate A (CSA) is a protein which is proved to exist on the surface of placental syncytiotrophoblasts and P-CSA-BP is effective for targeting lipid-polymer nanoparticle to the placenta (Zhang et al., 2018). This research indicates that sFLT1-siRNA-based PE therapy is a hopeful therapeutic strategy. The discovery of P-CSA-BP makes it possible to develop a placenta-specific sFLT1-siRNA delivery method, which is thought to be a great progression in the improvement of sFLT1-siRNA-based PE therapeutic strategy.

In this research, we built up P-CSA-BP-conjugated nanoparticles loaded with sFLT1 siRNA to generate a new placenta-specific siRNA delivery method. We aimed to illustrate the effects of this method in placenta targeting and silencing of sFLT1 and analyze the toxic effect.

Materials and Methods

Animals

Pregnant CD1 mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Mice were caged in pathogen-free animal room with 12 h light/12 h dark cycle. The gestation of mice was determined by checking vaginal plugs formation (E0.5 = vaginal plug day). At 14 and 15 days of gestation, the mice were treated by siRNA, NP_siRNA, or T-NP_siRNA through intravenous injection in the tail vein at the siRNA dosage of 2 mg/kg. The accumulation of Cy5-labeled sisFLT1 in mice placenta was observed through ex vivo images. Placenta tissue samples and blood samples were collected for further investigation. The procedures of animal experiments in this research were approved by the Shandong Provincial Hospital Affiliated to Shandong University.

Cell Culture

HTR-8/SVneo cell lines were obtained from the American Type Culture Collection (ATCC, VA, United States). RPMI-1640 medium (Gibco, New York, United States) with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Sigma, St. Louis, United States) was applied for the cell culture under the standard conditions.

Preparation and Characterization of Nanoparticles

Lipid-polymer nanoparticles loaded with sFLT1 siRNAs (NP_sisFLT1) were synthesized from carboxyl-polyethylene glycol-poly(D,L-lactide) (COOH-PEG_5K-PLA_8K), cationic lipid DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimeth ylammonium chloride), and sFLT1 siRNAs using double emulsion method which was previously published in other research (Xu et al., 2016). Synthetic placental CSA-binding peptides (P-CSA-BP) were conjugated to NP_sisFLT1 to generate the trophoblast-targeted nanoparticles (T-NP_sisFLT1) based on the method from other study (Zhang et al., 2018).

Size distribution and zeta potential of nanoparticles were measured through dynamic light scattering (DLS) in triplicate with the help of Zetasizer Nano ZS (Malvern, United Kingdom). The morphology of nanoparticles was visualized through transmission electron microscopy (TEM) (JEOL-2010 microscopy, Tokyo, Japan). The colloidal stability was investigated by incubating in phosphate buffered saline (PBS) with 10% fetal bovine serum (FBS) and analyzing the size of nanoparticles.

Gel Retardation Assay

The integrity of nanoparticles after 7 days’ incubation in PBS with 10% BSA was investigated by gel retardation assay. Naked siRNA was used as a control. Samples were mixed with gel loading buffer containing 1% SDS and separated by 2% agarose gel electrophoresis. The samples in gel were observed by ethidium bromide staining.

Immunohistochemistry

Immunohistochemistry was employed to evaluate CSA expression in placenta tissues. After being deparaffinized and rehydrated, slides were treated by antigen retrieval buffer. Then the tissue sections were incubated with BSA for 1 h at room temperature. Then the sections were incubated with mouse monoclonal anti-chondroitin sulfate antibody (Abcam, Cambridge, United Kingdom) or control IgG (Abcam) at 4°C overnight. After being washed, the sections were incubated with HRP-donkey anti-mouse IgG (ThermoFisher, Waltham, United States). The sections were observed under a light microscope.

Immunofluorescence

Cells were fixed by 4% paraformaldehyde for 30 min at room temperature and permeabilized by 0.05% Triton X-100 for 10 min. After being blocked by 5% BSA for 1 h at room temperature, cells were incubated with anti-chondroitin sulfate antibody (Abcam) at 4°C overnight. After being washed by PBS for three times, the cells were incubated with anti-mouse IgG FITC antibody (Abcam) for 1 h at room temperature. Cell nucleus were stained with DAPI. Cells were observed by confocal microscope.

Flow Cytometry

5 × 10⁴ HTR-8/SVneo cells were planted in each well of a 24-well plate. After 24 h, cells were incubated with free Cy5 labeled siRNA (Cy5-siRNA), NP_Cy5–siRNA, or T-NP_Cy5–siRNA (100 nM) for 4 h. After incubation, cells were collected and analyzed by FACSCalibur (BD Biosciences, Bedford, United States). Mean fluorescence intensity of Cy5 was calculated by FlowJo 7.6.1 software.

ELISA

fms-like tyrosine kinase 1 protein levels in cell medium or serum were evaluated by ELISA kit (R&D Systems, Minneapolis, United States) based on the manufacturer’s instructions. Experiments were done in duplicate, and the protein levels were calculated using a standard curve. The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of mice were analyzed by colorimetric assay kits (Sigma, St. Louis, United States) based on the manufacturer’s instructions.

Real-Time PCR

Trizol reagent (Invitrogen, Waltham, MA, United States) was used for the extraction of total RNA. First Strand cDNA Synthesis Kit (Sigma, St. Louis, MO, United States) was employed to synthesis cDNA from relative RNA. Real-time PCR was executed by SYBR Green Real-Time PCR Master Mixes (ThermoFisher, Waltham, MA, United States) following manufacturer’s instruction. β-actin and GAPDH were employed as internal control. All the primers were shown here:

Human sFLT-1 F: GAAATGGTGAGTAAGGAAAGC

Human sFLT-1 R: TACTGTCCCAGATTATGCGTTT

Human β-actin F: CTGGTGCCTGGGGCG

Human β-actin R: AGCCTCGCCTTTGCCG

Mouse sFlt-1 F: CGACTCACTATAGGGAGACCC

Mouse sFlt-1 R: TGGCCTGCTTGCATGATGTGCTGG

Mouse GAPDH F: GTGGCAAAGTGGAGATTGTTGCC

Mouse GAPDH R: GATGATGACCCGTTTGGCTCC

High-Performance Liquid Chromatography (HPLC)

High-performance liquid chromatography was employed to evaluate the amount of sisFLT1 accumulated in different tissues. Tissues were harvested 1 day after injection. The performance of HPLC was based on the standard method (Zhang et al., 2018). One day after injection, relative tissues were collected and homogenized in PBS. 10% perchloric acid was added into the mixture and vortexed for 3 min. After being centrifuged at 14,000 × g for 20 min, supernatants were collected and filtered (0.45 μm). Mobile phase was composed of 40 mM potassium phosphate dibasic and acetonitrile. Flow rate was 1.0 mL/min. Ultraviolet absorbance at 313 nm was detected.

Statistical Analysis

Statistical analysis was performed by GraphPad PRISM 6.0 software. Data were presented as mean ± SD. Student’s t-test, one or two-way ANOVA analysis with a post hoc test were used to calculate the differences. Statistical analysis was significant when P value < 0.05.

Results

The Preparation and Characterization of Trophoblast-Targeted sFLT1 siRNA-Encapsulated Nanoparticles

As shown in Figure 1A, NP_sisFLT1 was constructed from COOH-PEG_5K-PLA_8K, DOTAP, and sisFLT1 through double emulsion method and T-NP_sisFLT1 was fabricated by conjugating P-CSA-BP to the surface of NP_sisFLT1. DLS results shown that the resulted nanoparticles T-NP_sisFLT1 had a relative larger particle size than NP_sisFLT1 (Figure 1B). The conjugation of P-CSA-BP enlarged the size of the nanoparticle. The morphology of these two nanoparticles was checked by TEM and the representative TEM images were shown in Figure 1C. The P-CSA-BP could be observed on the surface of T-NP_sisFLT1. Both of the nanoparticles had slightly positive zeta potentials (Figure 1D). The incubation of siRNA-encapsulated nanoparticles in PBS demonstrated the colloidal stability of these two nanoparticles (Figure 1E). Based on the results of agarose gel retardation assay, no significant siRNA release was observed, indicating that both nanoparticles were successfully protected the encapsulated siRNA (Figure 1F). So, nanoparticles T-NP_sisFLT1 was successfully generated from NP_sisFLT1 and was proved to be stable.

FIGURE 1

Figure 1. Preparation of trophoblast-targeted nanoparticles encapsulating sFLT1 siRNA. (A) Nanoparticles loaded with sFLT1 siRNA (denoted as NP_sisFLT1) was constructed from COOH-PEG_5K-PLA_8K, cationic lipid DOTAP, and sisFLT1 using double emulsion method. Trophoblast-targeted nanoparticles (denoted as T-NP_sisFLT1) was fabricated by conjugating peptides, which could specific bind with CSA on the trophoblasts, to the surface of NP_sisFLT1. (B) Size distributions of NP_sisFLT1 and T-NP_sisFLT1 were examined by DLS. (C) Representative TEM images of NP_sisFLT1 and T-NP_sisFLT1. Scale bars = 100 nm. (D) Zeta potential of nanoparticles examined via DLS. (E) Effect of incubation in PBS on the particle size. (F) Gel retardation assay for examining the integrity of nanoparticles 7-day post construction.

T-NP_siRNA Specifically Target Trophoblast Cells in vitro

Chondroitin sulfate A is a protein which is proved to exist on the surface of placental syncytiotrophoblasts. Through the immunohistochemistry, we proved the expression of CSA in the tissue of mouse placenta (Figure 2A). HTR-8/SVneo cells were human trophoblast cells and the expression of CSA was observed through immunofluorescence (Figure 2B). To investigate the uptake of these two kinds of nanoparticles into HTR-8/SVneo cells, siRNA was labeled with Cy5 and cells were analyzed by flow cytometry after incubating with nanoparticles. Based on the result of flow cytometry, trophoblast cells incubated with T-NP_Cy5–siRNA had a significantly higher Cy5 signal intensity than those incubated with NP_Cy5–siRNA (Figures 2C,D). Furthermore, the internalized NP_Cy5–siRNA and T-NP_Cy5–siRNA in HTR-8/SVneo cells were observed by confocal microscopy (Figure 2E). These results indicated that T-NP_siRNA had a higher efficiency than NP_siRNA in targeting to trophoblast cells in vitro.

FIGURE 2

Figure 2. T-NP_Cy5–siRNA specifically target trophoblast cells in vitro. (A) The expression of CSA in mouse placenta was examined by immunohistochemistry. Scale bar = 20 μm. (B) The expression of CSA on HTR-8/SVneo cells was examined by confocal microscopy. CSA was stained with IgG isotype control antibody or anti-CSA primary antibody and anti-mouse IgG (whole molecule) FITC antibody. Scale bar = 10 μm. (C) Flow cytometry analyses of HTR-8/SVneo cells after 4 h incubation with free Cy5 labeled siRNA (Cy5-siRNA), NP_Cy5–siRNA and T-NP_Cy5–siRNA, the siRNA concentration was 100 nM. (D) Mean fluorescence intensity of Cy5 in HTR-8/SVneo cells after treated with Cy5-siRNA, NP_Cy5–siRNA and T-NP_Cy5–siRNA. (E) Intracellular uptake of Cy5-siRNA, NP_Cy5–siRNA and T-NP_Cy5–siRNA were examined by confocal microscopy. Cell nuclei were stained with DAPI; the cytoskeleton was stained with Alexa Fluor 488 Phalloidin. Scale bar = 20 μm. Data was shown as mean ± SD. ***p < 0.001.

T-NP_sisFLT1 Inhibit the Expression of sFLT1 in vitro

To demonstrate the function of these two sFLT1 siRNA-encapsulated nanoparticles in the inhibition of sFLT1 expression in vitro, HTR-8/SVneo cells were treated with free si_sFLT1, NP_sisFLT1 or T-NP_sisFLT1 for 48 h. The mRNA levels of sFLT1 in cells were evaluated through RT-PCR and the results were shown in Figure 3A. When compared with cells treated by NP_sisFLT1, those cells treated by T-NP_sisFLT1 shown a significant lower sFLT1 mRNA level and this phenomenon was enhanced by the increasing dosage. The protein level of sFLT1 was evaluated by ELISA and shown the same tendency with mRNA (Figure 3B). The protein levels of sFLT1 in HTR-8/SVneo cells were not altered by the treatment of nanoparticles encapsulating nonsense siRNA (NP_siNC and T-NP_siNC) (Figure 3C). T-NP_sisFLT1 had a higher efficiency than NP_sisFLT1 in the inhibition of sFLT1 expression in trophoblast cells in vitro.

FIGURE 3

Figure 3. Efficient silencing of sFLT1 by T-NP_sisFLT1 in vitro. (A) Silencing of sFLT1 by different formulations in a dose-dependent manner. HTR-8/SVneo cells were treated with free sisFLT1, NP_sisFLT1 or T-NP_sisFLT1 for 48 h and sFLT1 mRNA levels were examined via RT-PCR. The final concentration of sisFLT1 was 100 nM or 200 nM in present study. (B) sFLT1 protein levels produced by HTR-8/SVneo cells treated with different formulations for 48 h. sFLT1 protein levels were measured by ELISA (n = 3). (C) sFLT1 protein levels produced by HTR-8/SVneo cells after treated with T-NP encapsulating nonsense siRNA (T-NP_siNC). Data was shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. ns. no significant difference.

T-NP_sisFLT1 Selectively Accumulate in Placenta and Downregulate sFLT1 Expression in Mice

The function of T-NP_sisFLT1 was further checked in mouse model. Experimental design for testing accumulation ability of T-NP_Cy5–siRNA in pregnant CD1 mice was shown in Figure 4A. To illustrate the accumulation of the nanoparticles, pregnant CD1 mice were intravenously injected with NP_Cy5–siRNA and T-NP_Cy5–siRNA. Based on the ex vivo examination, the localization of T-NP_Cy5–siRNA in placenta was much higher than NP_Cy5–siRNA (Figure 4B). HPLC was employed to quantitatively compare the accumulation of the nanoparticles in different organs. As shown in Figure 4C, the amount of Cy5-siRNA in the placenta of mice treated by T-NP_Cy5–siRNA was significantly higher than in the placenta of mice treated by NP_Cy5–siRNA. But the distribution of Cy5-siRNA shown no significant differences in other organs. So, P-CSA-BP on the surface of T-NP_sisFLT1 enhanced the nanoparticle’s specific accumulation ability in mice placenta. Experimental design for testing silencing ability of T-NP_sisFLT1 in pregnant CD1 mice was shown in Figure 4D. We examined the mRNA levels of sFLT1 in the placenta of mice treated by different nanoparticles through RT-PCR. When compared with NP_sisFLT1, the treatment of T-NP_sisFLT1 significantly decreased the mRNA level of sFLT1 in the placenta of mice (Figure 4E). Circulating sFLT1 levels in mice were evaluated by ELISA and shown the same tendency (Figure 4F). So, P-CSA-BP on the surface of T-NPsisFLT1 also enhanced the nanoparticle’s sFLT1 silencing ability in mice placenta. It was proved that T-NP_sisFLT1 had a higher efficiency than NP_sisFLT1 in accumulation in the placenta of mice and silencing sFLT1.

FIGURE 4

Figure 4. T-NP_sisFLT1 selectively accumulate in placenta and downregulate sFLT1 expression. (A) Experimental design for in vivo testing of T-NP_siRNA accumulation in pregnant CD1 mice. Pregnant CD1 mice treated with T-NP encapsulating Cy5-labeled sisFLT1 at 14 days of gestation, and the injection dosage of Cy5-sisFLT1 was 2 mg/kg. The biodistribution of T-NP_Cy5–siRNA was qualitatively and quantitively detected 1 day later. (B) Ex vivo images of placenta in the pregnant mice after Cy5-labled siRNA injection at 15 days of gestation. (C) Amount of Cy5 accumulated in indicated tissues 1 day after injection using HPLC. (D) Experimental design for in vivo silencing of sFLT1 via NP_sisFLT1. Pregnant CD1 mice were intravenously injected with 2 mg/kg of sisFLT1 on pregnancy days 14 and 15 days of gestation, and killed for examination on allowed to deliver pups on 19 days of gestation or allowed to delivery. Blood was collected on the indicated days. (E) sFLT1 mRNA expression in placenta on 19 days of gestation examined via RT-PCR (n = 8 biologically independent animals). (F) Circulating sFLT1 levels from mice injected with free sisFLT1, NP_sisFLT1 or T-NP_sisFLT1 measured by ELISA (n = 8 biologically independent animals). Data was shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.

Conjugating P-CSA-BP to the Surface of NP_sisFLT1 Does Not Enhance the Toxic Effect

We further investigated whether conjugating P-CSA-BP to the surface of NP_sisFLT1 enhanced the nanoparticle’s toxic effect in mice. The changes of ALT and AST were widely used for illustrating the severity of the toxic effect on liver. The levels of the maternal liver transaminases ALT and AST in mice was analyzed after treatment. The normal ALT and AST levels indicated that the treatment of NP_sisFLT1 or T-NP_sisFLT1 had no obvious adverse effects (Figures 5A,B). We also checked the influence of these nanoparticles on the fetus. Both newborn pup number and weight were not influenced by the treatment of NP_sisFLT1 or T-NP_sisFLT1 (Figures 5C,D). Both of these two nanoparticles had low maternal and fetal toxic effect. Thus, conjugating P-CSA-BP to the surface of NPsisFLT1 did not enhance the nanoparticle’s toxic effect in mice.

FIGURE 5

Figure 5. Toxic effect analysis of T-NP_sisFLT1. Enzyme activities of ALT (A) and AST (B) at day 19 of gestation in mice injected with free sisFLT1, NP_sisFLT1 or T-NP_sisFLT1 (n = 8 biologically independent animals). Newborn pup number (C) and weights (D) from mice injected with free sisFLT1, NP_sisFLT1 or T-NP_sisFLT1 (n = 8 biologically independent animals). ns. no significant difference.

Discussion

Based on previous research, the pathogenesis of PE can be divided into two different stages (Redman and Sargent, 2009). The first stage is asymptomatic, but abnormal placenta formation and accumulation of placenta released factors in maternal circulation can be observed. The symptomatic second stage is characterized by placental oxidative stress, hypertension and proteinuria, that eventually result in angiospasm in brain which caused eclampsia (Hladunewich et al., 2007). Since the molecular mechanism during the pathogenesis of PE is not fully understand, PE still lacks reliable method for prediction and diagnosis and effective therapeutic strategy (Ahmed et al., 2017). Untreated PE is life threatening and will develops into eclampsia with several severe complications (Arulkumaran and Lightstone, 2013). Till now, the only effective therapy for PE is the early delivery of the pregnancy.

In recent years, the pathogenesis of PE is proved to have a strong correlation with the factors generated and released from placenta (Levine et al., 2004). Several different researches have demonstrated the abnormal increased level of anti-angiogenic molecule sFLT-1 in the circulation of women with PE (He et al., 1999; Maynard et al., 2003). The accumulation of sFLT-1 has a strong correlation with the generation of hypertension through its function in antagonizing VEGF and PlGF (Fan et al., 2014). The sFLT-1/PlGF ratio is reported to be useful for the diagnosis and prognosis assessment of PE (Herraiz et al., 2018). sFLT-1 is also considered as a potential PE therapeutic target. Thadhani et al. (2016), have proved that apheresis therapy is efficient in removing sFLT-1 in the circulation of women with PE and extends the pregnancies with no obvious adverse effects on both mother and fetus. Brownfoot et al. (2016), demonstrated that metformin inhibits the production of sFLT-1 in villous trophoblast and prevents the pathogenesis of PE. In both mouse and baboon PE model, systemically delivered modified sFLT1 siRNAs accumulate in placentas, inhibit sFLT1 expression, and alleviate hypertension and proteinuria (Turanov et al., 2018). RNAi-based placental sFLT1 expression modulation is proved to be a novel therapeutic approach for PE. However, several limitations still exist in the development of this therapeutic strategy, such as siRNA degradation and difficulty in crossing cell membrane (Liu et al., 2014).

Nanoparticles can act as delivery system and have several benefits, including enhanced permeability, retention effect, and extravasation ability and are widely used in the therapy of cancer and other disease (Cheng et al., 2015). The transfer ability of nanoparticles to different organs is critical for the therapy. It is reported that molecular shape, surface modification, and particle size determine whether the nanoparticle can cross the placenta barrier (Muoth et al., 2016). Poly-amidoamine (PAMAM) dendrimers are shown to be excellent nanocarrier for siRNA delivery and siRNA-sFLT1-PAMAM complex is proved to be effective in inhibition sFLT1 expression and improving pregnancy outcomes in PE rat model (Yu et al., 2017). PEG-PLA nanoparticle generated by double-emulsion methods is a novel siRNA delivery system which is proved in both in vivo and in vitro cancer models (Yang et al., 2011). We aimed to use this PEG-PLA nanoparticular system for the delivery of sFLT1 siRNA into placenta and inhibiting the pathogenesis of PE.

Despite the placenta is unrestricted exposed to drugs in maternal circulation, only a small proportion of non-targeted nanoparticles are successfully transported into placenta (Zhang et al., 2018). Thus, specific targeting the nanoparticles to placental tissues is critical for the development of nanoparticle-based therapeutic strategy for pregnancy-related disorders. CSA is a protein which exist on placental syncytiotrophoblasts. We confirmed the existence of CAS in both mice placenta tissues and human trophoblast HTR-8/SVneo cells. Synthetic placental CSA-binding peptide can specifically bind to trophoblasts in placenta but not to other cells expressing CSA in other tissues. It is reported that P-CSA-BP-conjugated nanoparticles is effective in targeting to the placenta and is a novel placenta-specific drug delivery option (Zhang et al., 2018). Based on the PEG-PLA nanoparticular system, we synthesized P-CSA-BP-conjugated PEG-PLA nanoparticles encapsulating sFLT1 siRNA and analyzed its function both in vivo and in vitro. Conjugating P-CSA-BP enlarged the particle size and decreased the surface potential of PEG-PLA nanoparticles. Both NP_sisFLT1 and T-NP_sisFLT1 nanoparticles were proved to be stable in PBS and shown strong ability in the protection of encapsulated siRNA. HTR-8/SVneo cells were generated from isolated first trimester extravillous cytotrophoblasts through the infection with simian virus 40 large T antigen (Abou-Kheir et al., 2017). In human trophoblast HTR-8/SVneo cells, the existence of P-CSA-BP on the surface of nanoparticles significantly enhanced its accumulation ability, which was shown by both flow cytometry analyses and immunofluorescence results. We also checked the efficiency of NP_sisFLT1 and T-NP_sisFLT1 nanoparticles in targeting to the placentas of pregnant CD1 mice. Ex vivo images and HPLC results demonstrated that nanoparticles with P-CSA-BP on the surface had a significantly stronger ability in accumulation in the placenta of mice. So, conjugating P-CSA-BP to the surface of PEG-PLA nanoparticles enhanced its ability in targeted delivery of drugs to the placenta.

In this research, we aimed to decrease the expression of sFLT1 in placenta through the trophoblast-targeted nanoparticles encapsulating sFLT1 siRNA. In HTR-8/SVneo cells, T-NP_sisFLT1 nanoparticles had a higher efficiency in inhibition of sFLT1 expression than NP_sisFLT1 nanoparticles, which was shown in both mRNA and protein levels. Also, after being injected into pregnant CD1 mice, T-NP_sisFLT1 nanoparticles significantly decreased the sFLT1 mRNA level in placenta and sFLT1 protein level in serum. Trophoblast-targeted sFLT1 siRNA-encapsulated T-NP_sisFLT1 nanoparticles had a strong ability in the inhibition of sFLT1 expression in placenta and decreasing the amount of sFLT1 in circulation.

Nanoparticles used as delivery system in the therapy of PE must be safe for both mother and fetus. It should have no adverse effects on tissues, do not cross the placenta into fetus, and show no apparent fetal toxicity. The injection of T-NP_sisFLT1 nanoparticles did not influenced the enzyme activities of ALT and AST in pregnant mice. Meanwhile, the newborn pups number and weights were also not changed. These results illustrated that the utility of T-NP_sisFLT1 nanoparticles as a sFLT1 siRNA placenta specific delivery system was safe in mice.

In order for this placenta targeted nanoparticles to be adopted and accepted clinically, further research and development are required. The maximum dosage of this nanoparticles should be tested. The nanoparticles should be optimized to improve the efficiency in encapsulating and releasing sFLT1 siRNA. More toxicity tests should be performed in different animal models to ensure the safety of this nanoparticles. Although we had demonstrated sFLT1 silencing function of T-NPsisFLT1 nanoparticles in mouse placenta, but its effects in the prevention or therapy against PE in mice was not investigated. So, further studies should be done to demonstrate the function of T-NPsisFLT1 nanoparticles in PE therapy.

In conclusion, the employment of T-NP_sisFLT1 nanoparticles as a sFLT1 siRNA placenta specific delivery system significantly silenced sFLT1 in mice and was safe for both the mother and fetus. This nanoparticle might serve as a novel potential therapeutic strategy for PE.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement

The animal study was reviewed and approved by the Shandong Provincial Hospital Affiliated to Shandong University.

Author Contributions

LL, HY, and PC conceived the study. TX, QZ, DW, and YZ designed the experiments and analyzed the data. SW secured the funding and supervised the project.

Funding

This study was supported by the Key Research & Development Project of Shandong Province (2019GSF108096), the National Natural Science Foundation of China (81801473, 81971409, 81741037, 81741038, and 81100447), the Shandong Medical and Health Technology Development Program of China (2016WS0412), the Chongqing Postdoctoral Research Special Funding Project (XmT2018077), the China Postdoctoral Science Foundation (2018M631067 and 2019T120814), the Open Project of NHC Key Laboratory of Fertility Control Technology (2018KF002), and the Jinan Science and Technology Program (201907011 and 201907012).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

sFLT-1, fms-like tyrosine kinase 1; P-CSA -BP, Synthetic placental CSA binding peptide; PE, preeclampsia.

References

Abou-Kheir, W., Barrak, J., Hadadeh, O., and Daoud, G. (2017). HTR-8/SVneo cell line contains a mixed population of cells. Placenta 50, 1–7. doi: 10.1016/j.placenta.2016.12.007

PubMed Abstract | CrossRef Full Text | Google Scholar

Ahmad, S., and Ahmed, A. (2004). Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884–891. doi: 10.1161/01.RES.0000147365.86159.f5

PubMed Abstract | CrossRef Full Text | Google Scholar

Ahmed, A., Rezai, H., and Broadway-Stringer, S. (2017). Evidence-based revised view of the pathophysiology of preeclampsia. Adv. Exp. Med. Biol. 956, 355–374. doi: 10.1007/5584_2016_168

PubMed Abstract | CrossRef Full Text | Google Scholar

Anderson, U. D., Olsson, M. G., Kristensen, K. H., Akerstrom, B., and Hansson, S. R. (2012). Review: biochemical markers to predict preeclampsia. Placenta 33, S42–S47. doi: 10.1016/j.placenta.2011.11.021

PubMed Abstract | CrossRef Full Text | Google Scholar

Arulkumaran, N., and Lightstone, L. (2013). Severe pre-eclampsia and hypertensive crises Best. Pract. Res. Clin. Obstet. Gynaecol. 27, 877–884. doi: 10.1016/j.bpobgyn.2013.07.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Brownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., et al. (2016). Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am. J. Obstet. Gynecol. 214, e351–e356. doi: 10.1016/j.ajog.2015.12.019

PubMed Abstract | CrossRef Full Text | Google Scholar

Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., and Saltzman, W. M. (2015). A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 14, 239–247. doi: 10.1038/nrd4503

PubMed Abstract | CrossRef Full Text | Google Scholar

Douglas, K. A., and Redman, C. W. (1994). Eclampsia in the United Kingdom. BMJ 309, 1395–1400. doi: 10.1136/bmj.309.6966.1395

PubMed Abstract | CrossRef Full Text | Google Scholar

Fan, X., Kambham, N., Sung, J. F., Singh, N., Petitt, M., Dhal, S., et al. (2014). Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J. Clin. Invest. 124, 4941–4952. doi: 10.1172/JCI76864

PubMed Abstract | CrossRef Full Text | Google Scholar

He, H., Venema, V. J., Gu, X., Venema, R. C., Marrero, M. B., and Caldwell, R. B. (1999). Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274, 25130–25135. doi: 10.1074/jbc.274.35.25130

PubMed Abstract | CrossRef Full Text | Google Scholar

Henderson, J. T., Whitlock, E. P., O’Connor, E., Senger, C. A., Thompson, J. H., and Rowland, M. G. (2014). Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Prevent. Serv. Task Force Ann. Intern. Med. 160, 695–703. doi: 10.7326/M13-2844

PubMed Abstract | CrossRef Full Text | Google Scholar

Herraiz, I., Llurba, E., Verlohren, S., and Galindo, A., and Spanish Group for the Study of Angiogenic Markers in Preeclampsia. (2018). Update on the diagnosis and prognosis of preeclampsia with the Aid of the sFlt-1/PlGF ratio in singleton pregnancies. Fetal. Diagn. Ther. 43, 81–89. doi: 10.1159/000477903

PubMed Abstract | CrossRef Full Text | Google Scholar

Hladunewich, M., Karumanchi, S. A., and Lafayette, R. (2007). Pathophysiology of the clinical manifestations of preeclampsia. Clin. J. Am. Soc. Nephrol. 2, 543–549. doi: 10.2215/CJN.03761106

PubMed Abstract | CrossRef Full Text | Google Scholar

Laresgoiti-Servitje, E. (2013). A leading role for the immune system in the pathophysiology of preeclampsia. J. Leukoc. Biol. 94, 247–257. doi: 10.1189/jlb.1112603

PubMed Abstract | CrossRef Full Text | Google Scholar

Levine, R. J., Campos-Galicia, I., Berumen-Lechuga, M. G., Molina-Pérez, C. J., García-Paleta, Y., Isordia-Salas, I., et al. (2004). Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683. doi: 10.1056/NEJMoa031884

PubMed Abstract | CrossRef Full Text | Google Scholar

Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., et al. (2006). Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355, 992–1005. doi: 10.1056/NEJMoa055352

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, C., Liu, X., Rocchi, P., Qu, F., Iovanna, J. L., and Peng, L. (2014). Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo. Bioconjug. Chem. 25, 521–532. doi: 10.1021/bc4005156

PubMed Abstract | CrossRef Full Text | Google Scholar

Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., et al. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658. doi: 10.1172/JCI17189

PubMed Abstract | CrossRef Full Text | Google Scholar

Muoth, C., Aengenheister, L., Kucki, M., Wick, P., and Buerki-Thurnherr, T. (2016). Nanoparticle transport across the placental barrier: pushing the field forward! Nanomedicine 11, 941–957. doi: 10.2217/nnm-2015-0012

PubMed Abstract | CrossRef Full Text | Google Scholar

Palm, M., Basu, S., Larsson, A., Wernroth, L., Akerud, H., and Axelsson, O. (2011). A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet. Gynecol. Scand. 90, 1244–1251. doi: 10.1111/j.1600-0412.2011.01186.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Rana, S., Powe, C. E., Salahuddin, S., Verlohren, S., Perschel, F. H., Levine, R. J., et al. (2012). Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911–919. doi: 10.1161/CIRCULATIONAHA.111.054361

PubMed Abstract | CrossRef Full Text | Google Scholar

Redman, C. W., and Sargent, I. L. (2009). Placental stress and pre-eclampsia: a revised view. Placenta 30(Suppl. A), S38–S42. doi: 10.1016/j.placenta.2008.11.021

PubMed Abstract | CrossRef Full Text | Google Scholar

Salahuddin, S., Lee, Y., Vadnais, M., Sachs, B. P., Karumanchi, S. A., and Lim, K. H. (2007). Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am. J. Obstet. Gynecol. 197, e21–e26. doi: 10.1016/j.ajog.2007.04.010

PubMed Abstract | CrossRef Full Text | Google Scholar

Thadhani, R., Hagmann, H., Schaarschmidt, W., Roth, B., Cingoez, T., Karumanchi, S. A., et al. (2016). Removal of soluble fms-like tyrosine Kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903–913. doi: 10.1681/ASN.2015020157

PubMed Abstract | CrossRef Full Text | Google Scholar

Turanov, A. A., Lo, A., Hassler, M. R., Makris, A., Ashar-Patel, A., Alterman, J. F., et al. (2018). RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36, 1164–1173. doi: 10.1038/nbt.4297

PubMed Abstract | CrossRef Full Text | Google Scholar

von Dadelszen, P., and Magee, L. A. (2014). Pre-eclampsia: an update. Curr. Hypertens. Rep. 16:454. doi: 10.1007/s11906-014-0454-8

PubMed Abstract | CrossRef Full Text | Google Scholar

World Health Organization [WHO] (2011). WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: WHO Guidelines Approved by the Guidelines Review Committee.

Google Scholar

Xu, C. F., Zhang, H. B., Sun, C. Y., Liu, Y., Shen, S., Yang, X. Z., et al. (2016). Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery. Biomaterials 88, 48–59. doi: 10.1016/j.biomaterials.2016.02.031

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, X. Z., Dou, S., Sun, T. M., Mao, C. Q., Wang, H. X., and Wang, J. (2011). Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J. Control Release 156, 203–211. doi: 10.1016/j.jconrel.2011.07.035

PubMed Abstract | CrossRef Full Text | Google Scholar

Yu, J., Jia, J., Guo, X., Chen, R., and Feng, L. (2017). Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. Placenta 58, 1–8. doi: 10.1016/j.placenta.2017.07.360

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, B., Tan, L., Yu, Y., Wang, B., Chen, Z., Han, J., et al. (2018). Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. Theranostics 8, 2765–2781. doi: 10.7150/thno.22904

PubMed Abstract | CrossRef Full Text | Google Scholar